Why Patients Switch GLP-1 Medications for Better Tolerance
Managing Constipation on Wegovy Through Strategic Medication Switching
Constipation on Wegovy affects approximately 20-30% of patients according to clinical trial data, but switching between GLP-1 medications can offer relief whilst maintaining weight management progress. Many patients transition from Mounjaro (tirzepatide) to Wegovy (semaglutide) when experiencing persistent digestive issues, as the different mechanisms may suit individual tolerances better. Tirzepatide targets both GLP-1 and GIP receptors, whilst semaglutide focuses solely on GLP-1 receptors, potentially causing different side effect profiles.
EverydayMeds facilitates smooth transitions between these prescription-only medicines with clinical oversight from our GPhC-registered pharmacy (#9012878). Our prescribers provide dose conversion guidance – typically, patients on Mounjaro 2.5mg may transition to Wegovy 0.5mg or 1mg depending on individual response and tolerance. The switching process involves a clinical assessment to ensure continuity of care and optimal dosing for your specific situation.
Wegovy Pricing Advantages When Switching from Other GLP-1 Medications
Switching to Wegovy can deliver significant cost savings compared to other GLP-1 medications. Our Wegovy pricing starts at £79.99 for the 0.25mg starter dose (with code FIRST40 for new customers), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Returning customers benefit from code DOSE25 applied at checkout for continued savings.
For patients requiring consistent dosing during transition periods, our Consistency bundles provide two pens of the same strength – Consistency 1mg (×2) costs £209.99, whilst Consistency 2.4mg (×2) maintenance supply is £419.99. Our Step-Up bundles like the Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99 support patients transitioning from other medications who need flexible dose escalation options.
Clinical Evidence for Constipation on Wegovy Management
In the STEP clinical trials (Wilding et al., NEJM, 2021), constipation on Wegovy was reported as generally mild to moderate and often transient, typically improving as patients adjusted to treatment. The trials demonstrated that gastrointestinal side effects, including constipation, were most common during dose escalation phases and often resolved with continued treatment.
MHRA monitoring data shows that switching between GLP-1 medications under clinical supervision can help patients find optimal tolerance levels whilst maintaining therapeutic benefits. EverydayMeds' clinical team reviews each switching case individually, considering previous medication responses and current symptom management needs.
How Wegovy's GLP-1 Mechanism Differs When Managing Digestive Issues
Wegovy works as a GLP-1 receptor agonist, mimicking the natural hormone that regulates appetite and gastric emptying, which can initially slow digestion and contribute to constipation. Unlike combination medications targeting multiple hormone pathways, Wegovy's focused GLP-1 action may provide different tolerability for patients experiencing persistent digestive issues on other treatments. The medication reduces appetite by acting on brain appetite centres whilst promoting feelings of fullness after smaller meals, which can affect normal bowel patterns initially. Many patients find that constipation on Wegovy improves after 4-8 weeks as their digestive system adapts to the medication's effects. This prescription-only medicine must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
EverydayMeds Switching Process for Constipation Management
Transitioning medications for constipation on Wegovy management begins with our 3-minute online clinical assessment, where you detail your current medication, doses, and side effect experiences. Our prescribers typically review switching requests within 3 working days (or 24 hours with express service), providing personalised dose conversion recommendations based on your previous treatment response. Once approved, next-day delivery ensures continuity of treatment through our temperature-controlled cold-chain system. Our clinical team remains available throughout your transition period to monitor progress and adjust dosing if needed. GPhC registration #9012878 ensures all switching protocols meet UK pharmaceutical standards.
Storage and Practical Considerations When Switching to Wegovy
Wegovy requires refrigeration at 2-8°C before first use, but offers superior room temperature stability compared to some alternatives – up to 6 weeks below 30°C once removed from the fridge. The FlexTouch pen system provides consistent dosing through the mandatory escalation schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. Patients switching from other medications may start at different points in this escalation based on clinical assessment. The once-weekly injection schedule maintains consistency whilst your digestive system adapts to the new medication. Proper storage ensures medication potency throughout your switching transition period.
Constipation on Wegovy: Switching Strategies for Long-Term Success
Successfully managing constipation on Wegovy through medication switching requires strategic timing and clinical oversight that EverydayMeds provides. Many patients benefit from switching during lower dose phases when side effects are typically most manageable, allowing gradual adaptation to Wegovy's specific mechanism. Our prescribers coordinate switching protocols to minimise treatment gaps whilst optimising digestive tolerance.
Long-term success with constipation on Wegovy often improves through the Switch & Save approach, where cost savings enable patients to maintain consistent treatment without financial pressure to discontinue. Patients report better adherence when switching eliminates both troublesome side effects and financial strain, leading to sustained weight management results over time.
Complete Your Wegovy Switch Today
Ready to address constipation on Wegovy through our Switch & Save programme? Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment now. New customers use code FIRST40 at checkout, whilst returning customers benefit from code DOSE25 for continued savings. Our prescribers specialise in GLP-1 medication transitions and provide ongoing support throughout your switching journey. Don't let digestive side effects derail your weight management progress when effective switching options exist. Start your assessment today and discover how the right medication match can transform your treatment experience.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
